Company: SXTPW
Filing Date: 2025-05-15
Form Type: 10-Q
Source: 0001213900-25-043779
Chunk: 116

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-05-15
Form: 10-Q
Item: Part I, Item 8
Chunk 116
---
 of common stock issuable upon exercise of the January
2025 Warrants. The registration statement was declared effective by the SEC on April 2, 2025. The Company shall use commercially reasonable
efforts to keep such registration statement effective at all times until no January 2025 Purchaser owns any January 2025 Warrants or shares
underlying the January 2025 Warrants issuable upon exercise thereof.

February 2025 Offering

On February 5, 2025, we entered into a securities
purchase agreement (the “February 2025 Securities Purchase Agreement”) with certain institutional investors (the “February
2025 Purchasers”) pursuant to which we sold an aggregate of 300,700 shares of common stock at a purchase price of $3.575 per share
in a registered direct offering priced at-the-market under the rules of Nasdaq. In a concurrent private placement, we also issued to the
February 2025 Purchasers unregistered warrants (the “February 2025 Warrants”) to purchase up to an aggregate of 300,700 shares
of common stock at an exercise price of $2.95 per share. The February 2025 Warrants are exercisable upon issuance and expire twenty-four
months from the date of issuance.

The shares were offered pursuant to a “shelf”
registration statement on Form S-3 (Registration No. 333-280796), which was declared effective by the Securities and Exchange Commission
(the “SEC”) on July 18, 2024 as supplemented by a prospectus supplement dated February 5, 2025, filed with the SEC on February
6, 2025 and accompanying base prospectus, pursuant to Rule 424(b)(5) promulgated under the Securities Act.

The Placement Agent acted as our exclusive placement
agent in connection with the offering. Pursuant to the terms of the placement agent agreement, we paid the Placement Agent a cash transaction
fee equal to 7.5% of the aggregate gross cash proceeds in the offering and a management fee equal to 1.0% of the aggregate gross cash
proceeds in the offering. In addition, we paid for certain non-accountable expenses in the amount of $15,000 and a clearing fee in the
amount of $10,000. We also issued to the Placement Agent (or its designees) warrants to purchase up to 22,554 shares of Common Stock (the
“February 2025 Placement Agent Warrants”). The